Latest news with #iPSC
Yahoo
27-05-2025
- Business
- Yahoo
Induced Pluripotent Stem Cell (iPSC) Industry Report 2025-2030: iPSCs Set to Redefine Clinical and Research Paradigms, iPSC Technology Drives Innovation in Regenerative Therapy
Dublin, May 27, 2025 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2025" has been added to offering. The market for iPSC-derived products continues expanding with involvement from companies like Lonza, BD Biosciences, and Thermo Fisher Scientific, among others. Over 90 companies actively engage in this market, offering diverse products and technologies for research and therapeutic applications. Since discovering iPSCs 18 years ago, remarkable advancements have occurred. It saw its first human application in 2013, and now at least 155 clinical trials use iPSCs globally. iPSCs are being tested for various conditions, including Parkinson's disease, cancer immunotherapies with iNK cells, age-related macular degeneration, and Type 1 diabetes. This diversity underscores iPSCs' transformative potential in treating numerous diseases. Commercially, companies harness iPSC products for drug development, disease modeling, and toxicology testing. Notable players include FUJIFILM Cellular Dynamics International (FCDI), a leader in iPSC-derived human cell production, and ReproCELL, pioneering iPSC product commercialization. Europe also hosts major competitors like Evotec and Ncardia, specializing in drug screening and cardiac applications, respectively. The potential of iPSCs to redefine medicine and biotechnology is substantial. As iPSC applications evolve in disease modeling, drug discovery, and cell therapies, they drive innovation within healthcare and research, paving the way for transformative advancements. This comprehensive report outlines key players, strategic partnerships, and innovations propelling the sector. It details advancements in iPSC research, manufacturing, and clinical developments, alongside an analysis of the funding landscape. Projected market growth rates through 2030, categorized by application, technology, cell types, and geography, offer insights into iPSC industry's future. Current Commercialization Methods of iPSCs: Cellular Therapy: iPSCs are being explored for cell therapy applications to repair injuries or cure diseases by substituting damaged cells. Disease Modeling: Patient-specific iPSCs are differentiated into disease-specific cells, creating functional models for research. Drug Development: iPSCs deliver physiologically relevant cells for drug discovery, enhancing the efficacy of compound identification, target validation, and screening processes. Personalized Medicine: Integration with genome-editing technologies facilitates customized treatments by modifying iPSCs at the genetic level. Toxicology Testing: Screening iPSCs or derivatives to evaluate compound safety and efficacy reduces dependence on animal testing. Tissue Engineering: Culturing iPSCs on biocompatible scaffolds supports engineered tissue development for transplantation. Organoid Production: Self-organizing iPSCs form 3D organoids, facilitating organ study, disease modeling, and drug testing. Gene Editing: Techniques like CRISPR enable iPSC modifications for mutation correction, facilitating functional cell development for treatments. Research Tools: Extensive research applications include studying cellular processes and testing experimental therapies with iPSCs. Stem Cell Banking: iPSC repositories offer diverse cell types for research, allowing investigations into conditions using samples from various donors. Cultured Meat Production: iPSCs serve as cellular bases for lab-grown meat production, promoting sustainable alternatives. 3D Bioprinting: Differentiated iPSCs are used in bioinks for creating complex tissue structures via 3D bioprinting. Key Topics Covered: 1. REPORT OVERVIEW1.1 Statement of the Report1.2 Executive Summary 2. INTRODUCTION 3. CURRENT STATUS OF IPSC INDUSTRY3.1 Progress made in Autologous Cell Therapy using iPSCs3.2 Allogeneic iPSC-based Cell Therapies3.3 Share of iPSC-based Research within the Overall Stem Cell Industry3.4 Major Focus Areas of iPSC Companies3.5 Commercially Available iPSC-derived Cell Types3.6 Relative use of iPSC-derived Cell Types in Toxicology Testing Assays3.7 iPSC-derived Cell Types used in Clinical Trials3.8 Currently Available iPSC Technologies 4. HISTORY OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)4.1 First iPSC Generation from Mouse Fibroblasts, 20064.2 First Human iPSC Generation, 20074.3 Creation of CiRA, 20104.4 First High-Throughput Screening using iPSCs, 20124.5 First iPSC Clinical Trial Approved in Japan, 20134.6 First iPSC-RPE Cell Sheet Transplantation for AMD, 20144.7 EBiSC Founded, 20144.8 First Clinical Trial using Allogeneic iPSCs for AMD, 20174.9 Clinical Trial for Parkinson's Disease using Allogeneic iPSCs, 20184.10 Commercial iPSC Plant SMaRT Established, 20184.11 First iPSC Therapy Center in Japan, 20194.12 First U.S.-based NIH-Sponsored Clinical Trial using iPSCs, 20194.13 Cynata Therapeutics' World's Largest Phase III Clinical Trial, 20204.14 Tools and Know-how to Manufacture iPSCs in Clinical Trials, 20214.15 Production of in-house iPSCs using Peripheral Blood Cells, 2022 5. RESEARCH PUBLICATIONS ON IPSCS5.1 Rapid Growth in iPSC Publications 6. IPSC: PATENT LANDSCAPE ANALYSIS6.1 iPSC Patent Applications by Jurisdiction6.2 iPSC Patent Applicants6.3 Inventors of iPSC Patents6.4 iPSC Patent Owners6.5 Legal Status of iPSC Patents 7. IPSC: CLINICAL TRIAL LANDSCAPE7.1 Number of iPSC Clinical Trials7.1 Recruitment Status of iPSC Clinical Trials7.3 iPSC Clinical Trials Stydy Designs7.4 Therapeutic & Non-Therapeutic iPSC Clinical Trials7.5 iPSC-based Trials by Phase of Study7.6 iPSC Clinical Trials by Funder Type7.7 Geographic Distribution of iPSC-based Clinical Trials7.8 Promising iPSC Product Candidates7.9 Companies having Preclinical iPSC Assets 8. M&A, COLLABORATIONS & FUNDING ACTIVITIES IN IPSC SECTOR8.1 Mergers and Acquisitions (M&A) Sector8.2 Partnership/Collaboration & Licensing Deals in iPSC Sector8.3 Venture Capital Funding in iPSC Sector 9. GENERATION OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)9.1 OSKM Cocktail9.2 Pluripotency-Associated Transcription Factors and their Functions9.3 Delivery of Reprogramming Factors9.4 Genome Editing Technologies in iPSC Generation9.5 Available iPSC Lines and their applications 10. HUMAN IPSC BANKING10.1 Major Biobanks Storing iPSCs & iPSC Lines10.2 Cell Sources for iPSC Banks10.3 Reprogramming Methods in iPSC Banks10.4 Ownership and Investments made in iPSC Banks 11. BIOMEDICAL APPLICATIONS OF IPSCs11.1 iPSCs in Basic Research11.2 Applications of iPSCs in Drug Discovery11.3 Applications of iPSCs in Toxicology Studies11.4 Applications of iPSCs in Disease Modeling11.5 Applications of iPSCs in Cell-Based Therapies11.6 Other Novel Applications of iPSCs 12. MARKET ANALYSIS12.1 Global Market for iPSCs by Geography12.2 Global Market for iPSCs by Technology12.3 Global Market for iPSCs by Biomedical Application12.4 Global Market for iPSCs by Derived Cell Type12.5 Market Drivers12.6 Market Restraints 13. COMPANY PROFILES For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
Alloy Therapeutics Enters Japanese Market by Establishing Operations at Shonan Health Innovation Park
US-based biotech ecosystems company establishes subsidiary in key Japanese market with launch of its first cell therapy base in Japan, a key modality for Alloy to fully advance its proprietary iCAR-T technology. TOKYO & BOSTON, May 22, 2025--(BUSINESS WIRE)--Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, has recently opened its first location in Japan – at Shonan iPark in Kanagawa, one of the world's most advanced research facilities, where it is establishing a cell therapy base. To support its expansion into Japan, Alloy has formed Alloy Therapeutics Co., Ltd. and appointed Yoshihide Ishii (Victor Stone) as Chief Executive Officer of its Japanese subsidiary. Building on collaboration with Takeda announced in November 2024, Alloy will advance cell therapy leveraging its proprietary iCAR-T technology. Originating with the groundbreaking iPSC research of Nobel Laureate Shinya Yamanaka, the iCAR-T platform was developed through the T-CiRA program, led by Professor Shin Kaneko of Kyoto University's Center for iPS Cell Research and Application (CiRA) in collaboration with Takeda. The iCAR-T platform is noteworthy for (1) being the first iPS CAR-T technology to consistently deliver superior potency over autologous CAR-T in animal studies, and (2) enabling 'off-the-shelf' product profiles that significantly lower costs and increase access. Now, Alloy offers democratized access to this powerful cell therapy engine, combining best-in-class science with a fully integrated, scalable drug development platform. Alloy's iPS Center of Excellence As of this spring, 10 key members from Takeda's iCAR-T program have formally joined Alloy as founding members of Alloy Cell Therapies, creating the core of a fully integrated drug discovery program leveraging the iCAR-T platform. Alloy further welcomes Dr. Michael Kalos as an Executive Venture Partner of 82VS Venture Studios and a trusted advisor to Alloy Cell Therapies. Michael Kalos – Distinguished BioPharma Executive with key roles that span academia, pharma, and various biotech firms. Contributions include key discoveries that have shaped Immune Oncology and CAR-T development. "Cell Therapy has always been a key modality on our Technology roadmap, and we are thrilled with our partnership with Takeda and Kyoto University," said Errik Anderson, the CEO and founder of Alloy. "We are impressed with how advanced Cell Therapy is in Japan and we are excited to have the iCAR-T members join Alloy as the core members of Alloy's iPS Center of Excellence." "Cell Therapies gave us a compelling reason to establish our site in Japan. Cell Therapy is a stronghold in Japan, and this collaboration will allow Alloy to project the capabilities of Japanese science to the global biopharma markets," added Victor Stone, Chief Executive Officer of Alloy Japan. "Japan has many untapped strengths beyond Cell Therapies. Alloy will continue to expand its activities to leverage that potential, as well as build our franchise in this key market." About Alloy Therapeutics Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities: antibodies, bispecifics, TCRs, genetic medicines, cell therapies, and drug delivery. Partners may access all current and future technologies through a discovery service relationship or for a flat fee through Alloy's Innovation Subscriptions offering. As a reflection of Alloy's relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation. Join the Alloy Therapeutics community by visiting and following Alloy on LinkedIn. View source version on Contacts Victor Stone (Yoshihide Ishii)Chief Executive Officer of Alloy JapanEmail: celltherapies@ Chris BediHead of Strategic Marketing and Product ManagementEmail: communications@ Daniel BoglerEmail: AlloyTherapeutics-TYO@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22-05-2025
- Business
- Business Wire
Alloy Therapeutics Enters Japanese Market by Establishing Operations at Shonan Health Innovation Park
TOKYO & BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. ('Alloy'), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, has recently opened its first location in Japan – at Shonan iPark in Kanagawa, one of the world's most advanced research facilities, where it is establishing a cell therapy base. To support its expansion into Japan, Alloy has formed Alloy Therapeutics Co., Ltd. and appointed Yoshihide Ishii (Victor Stone) as Chief Executive Officer of its Japanese subsidiary. Building on collaboration with Takeda announced in November 2024, Alloy will advance cell therapy leveraging its proprietary iCAR-T technology. Originating with the groundbreaking iPSC research of Nobel Laureate Shinya Yamanaka, the iCAR-T platform was developed through the T-CiRA program, led by Professor Shin Kaneko of Kyoto University's Center for iPS Cell Research and Application (CiRA) in collaboration with Takeda. The iCAR-T platform is noteworthy for (1) being the first iPS CAR-T technology to consistently deliver superior potency over autologous CAR-T in animal studies, and (2) enabling 'off-the-shelf' product profiles that significantly lower costs and increase access. Now, Alloy offers democratized access to this powerful cell therapy engine, combining best-in-class science with a fully integrated, scalable drug development platform. Alloy's iPS Center of Excellence As of this spring, 10 key members from Takeda's iCAR-T program have formally joined Alloy as founding members of Alloy Cell Therapies, creating the core of a fully integrated drug discovery program leveraging the iCAR-T platform. Alloy further welcomes Dr. Michael Kalos as an Executive Venture Partner of 82VS Venture Studios and a trusted advisor to Alloy Cell Therapies. Michael Kalos – Distinguished BioPharma Executive with key roles that span academia, pharma, and various biotech firms. Contributions include key discoveries that have shaped Immune Oncology and CAR-T development. 'Cell Therapy has always been a key modality on our Technology roadmap, and we are thrilled with our partnership with Takeda and Kyoto University,' said Errik Anderson, the CEO and founder of Alloy. 'We are impressed with how advanced Cell Therapy is in Japan and we are excited to have the iCAR-T members join Alloy as the core members of Alloy's iPS Center of Excellence.' 'Cell Therapies gave us a compelling reason to establish our site in Japan. Cell Therapy is a stronghold in Japan, and this collaboration will allow Alloy to project the capabilities of Japanese science to the global biopharma markets,' added Victor Stone, Chief Executive Officer of Alloy Japan. 'Japan has many untapped strengths beyond Cell Therapies. Alloy will continue to expand its activities to leverage that potential, as well as build our franchise in this key market.' About Alloy Therapeutics Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities: antibodies, bispecifics, TCRs, genetic medicines, cell therapies, and drug delivery. Partners may access all current and future technologies through a discovery service relationship or for a flat fee through Alloy's Innovation Subscriptions offering. As a reflection of Alloy's relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation. Join the Alloy Therapeutics community by visiting and following Alloy on LinkedIn.
Globe and Mail
20-05-2025
- Business
- Globe and Mail
Trailhead Biosystems Announces David Llewellyn, PhD, MBA, as Chief Executive Officer
BEACHWOOD, Ohio , May 20, 2025 /CNW/ -- Trailhead Biosystems Inc. ( a biotechnology company pioneering the creation of iPSC-derived human cells at scale for drug discovery and cell therapy, is pleased to announce the appointment of David Llewellyn, PhD, MBA as its new Chief Executive Officer, and as a member of its Board of Directors. Dr. Llewellyn succeeds Jan Jensen , PhD, who has led the company as Chief Executive Officer and Chief Scientific Officer since its founding. Dr. Jensen will continue with Trailhead Biosystems as Chief Scientific Officer and Board member. "We are pleased to welcome Dr. Llewellyn to the company," said Michael Kaufman , Chairman of the Board of Trailhead Biosystems. "David brings with him over 20 years of experience commercializing life science products. His strong scientific and business acumen will be invaluable as Trailhead continues to innovate and expand." Dr. Jensen reflected on the transition, stating, "Trailhead Biosystems has reached an exciting inflection point, and bringing David Llewellyn on to the executive team marks the start of an ambitious new chapter. His expertise in life sciences and business strategy makes him the right leader to propel us onward, and I look forward to working alongside him to accelerate the commercialization of our groundbreaking technologies." Dr. Llewellyn began his career at MethylGene Inc. as a Medicinal Chemist where he developed a wide range of novel DNA methyltransferase inhibitors to treat cancer. He later joined Aquinox Pharmaceuticals, where he was involved in a variety of different activities including business development, financing and operations. Most recently, Dr. Llewellyn worked with STEMCELL Technologies Inc., where he held several top executive roles including Senior Vice President of Business Operations, Chief Commercial Officer, and Chief Strategy Officer. David holds a BSc in Chemistry from the University of Northern British Columbia , a PhD in Organic Chemistry from McGill University , and an MBA in Strategic Management from the University of British Columbia. "I am honored to step into the role of CEO and join the Board of Trailhead Biosystems," said Dr. Llewellyn. "Trailhead's proprietary High-Dimensional Design-of-Experiments Technology (HD-DoE ®) is a groundbreaking approach for making differentiated induced pluripotent stem cells, and there is no question that it's going to play an important role advancing stem cell research." Trailhead Biosystems is dedicated to revolutionizing medical research and the field of regenerative medicine by developing specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. Under Dr. Llewellyn's leadership, Trailhead plans to expand on its mission of advancing healthcare through scientific innovation with a strong commitment to commercial and scientific excellence.
Yahoo
20-05-2025
- Business
- Yahoo
Trailhead Biosystems Announces David Llewellyn, PhD, MBA, as Chief Executive Officer
BEACHWOOD, Ohio, May 20, 2025 /CNW/ -- Trailhead Biosystems Inc. ( a biotechnology company pioneering the creation of iPSC-derived human cells at scale for drug discovery and cell therapy, is pleased to announce the appointment of David Llewellyn, PhD, MBA as its new Chief Executive Officer, and as a member of its Board of Directors. Dr. Llewellyn succeeds Jan Jensen, PhD, who has led the company as Chief Executive Officer and Chief Scientific Officer since its founding. Dr. Jensen will continue with Trailhead Biosystems as Chief Scientific Officer and Board member. "We are pleased to welcome Dr. Llewellyn to the company," said Michael Kaufman, Chairman of the Board of Trailhead Biosystems. "David brings with him over 20 years of experience commercializing life science products. His strong scientific and business acumen will be invaluable as Trailhead continues to innovate and expand." Dr. Jensen reflected on the transition, stating, "Trailhead Biosystems has reached an exciting inflection point, and bringing David Llewellyn on to the executive team marks the start of an ambitious new chapter. His expertise in life sciences and business strategy makes him the right leader to propel us onward, and I look forward to working alongside him to accelerate the commercialization of our groundbreaking technologies." Dr. Llewellyn began his career at MethylGene Inc. as a Medicinal Chemist where he developed a wide range of novel DNA methyltransferase inhibitors to treat cancer. He later joined Aquinox Pharmaceuticals, where he was involved in a variety of different activities including business development, financing and operations. Most recently, Dr. Llewellyn worked with STEMCELL Technologies Inc., where he held several top executive roles including Senior Vice President of Business Operations, Chief Commercial Officer, and Chief Strategy Officer. David holds a BSc in Chemistry from the University of Northern British Columbia, a PhD in Organic Chemistry from McGill University, and an MBA in Strategic Management from the University of British Columbia. "I am honored to step into the role of CEO and join the Board of Trailhead Biosystems," said Dr. Llewellyn. "Trailhead's proprietary High-Dimensional Design-of-Experiments Technology (HD-DoE®) is a groundbreaking approach for making differentiated induced pluripotent stem cells, and there is no question that it's going to play an important role advancing stem cell research." Trailhead Biosystems is dedicated to revolutionizing medical research and the field of regenerative medicine by developing specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. Under Dr. Llewellyn's leadership, Trailhead plans to expand on its mission of advancing healthcare through scientific innovation with a strong commitment to commercial and scientific excellence. For more information, please contact:Tim Mauk, Corporate CommunicationsTrailhead BiosystemsEmail: info@ View original content to download multimedia: SOURCE Trailhead Biosystems Inc View original content to download multimedia:
